End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
16.67 MXN | +2.27% | +8.60% | +17.73% |
Summary
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
- With a P/E ratio at 13.39 for the current year and 7.72 for next year, earnings multiples are highly attractive compared with competitors.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The company is not the most generous with respect to shareholders' compensation.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last few months, analysts have been revising downwards their earnings forecast.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+17.73% | 917M | B+ | ||
+29.68% | 681B | C+ | ||
+20.15% | 556B | B | ||
-4.35% | 361B | C+ | ||
+17.65% | 325B | B- | ||
+3.77% | 285B | C+ | ||
+13.39% | 235B | B+ | ||
+4.42% | 199B | B- | ||
-12.39% | 189B | A+ | ||
-3.79% | 157B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- LAB B Stock
- Ratings Genomma Lab Internacional, S.A.B. de C.V.